相关实验视频
Updated: Apr 18, 2026

16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
35.3K
心力衰竭患者的血小板计数 接受左心室辅助装置的患者
Jun Luo1, Zhenhan Li2, Yuxiang Luo1
1Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
ESC heart failure
|June 4, 2024
概括
在接受左心室辅助装置 (LVAD) 植入的患者中,异常的植入前和植入后血小板 (PLT) 计数与更高的死亡风险有关. LVAD治疗可以帮助正常化PLT计数,改善结果.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
- 血液学 血液学 血液学
背景情况:
- 左心室辅助装置 (LVAD) 植入是末期心力衰竭的关键治疗方法.
- 众所周知,使用LVAD与血小板激活 (PLT) 和潜在的并发症有关.
研究的目的:
- 在接受连续流动LVADs的患者中调查植入前和植入后血小板计数的预后意义.
- 评估LVAD植入后血小板数的动态变化及其与长期存活的关联.
主要方法:
- 从INTERMACS注册表中分析了从19517名接受第一次连续流LVAD患者的数据.
- 根据植入前和植入后的血小板计数,患者被分为三层.
- 进行了统计分析,以评估血小板数量与长期死亡率之间的关联,包括U形曲线分析.
主要成果:
- 血小板计数显示,在LVAD植入后,血小板计数趋于正常化.
- 与中等计数相比,高和低的植入前血小板计数与2年死亡风险增加有关.
- 植入后血小板数量增加与4年死亡风险增加相关,这表明血小板数量和死亡率之间存在U形关联.
结论:
- 植入LVAD可以促进心力衰竭患者血小板数量的正常化.
- 在LVAD植入之前和之后,与正常血小板计数的偏差是增加长期死亡风险的独立预测因素.
相关概念视频
Heart Failure II: Pathophysiology
1.6K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.6K
Heart Failure V: Medical Management
592
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
592
Heart Failure VI: Adjunct Therapies
614
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
614
Cardiomyopathy II: Dilated Cardiomyopathy
807
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
807
Cardiomyopathy V: Interprofessional Care
724
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
724

